
In clinical trials of treatment for stimulant abuse, researchers commonly record both zzso zzso zzso self-reports and urine drug screen zzso zzso 

To compare the power of zzso qualitative zzso zzso no zzso zzso assessment, and various zzso to generate zzso composite measures to detect treatment differences via zzso in simulated clinical trial zzso 

We performed zzso Carlo simulations patterned in part on real data to model self-report zzso zzso zzso zzso zzso missing zzso reports, incomplete adherence to a urine donation schedule, zzso correlation of drug use, number of days in the study period, number of patients per arm, and distribution of zzso zzso zzso zzso include maximum likelihood and zzso estimates, self-report alone, zzso alone, and several simple modifications of self-report zzso to here as zzso zzso which eliminate perceived contradictions between it and zzso 

Among the zzso investigated, simple zzso zzso gave rise to the most powerful zzso to detect mean group differences in stimulant drug zzso 

Further investigation is needed to determine if simple, zzso procedures such as the zzso zzso are optimal for comparing clinical study treatment zzso But researchers who currently require an automated zzso in scenarios similar to those simulated for combining zzso and zzso to test group differences in stimulant use should consider one of the zzso zzso 

This analysis continues a line of inquiry which could determine how best to measure zzso stimulant use in clinical trials zzso zzso zzso zzso zzso of zzso Drug zzso Meeting Current Challenges to zzso zzso zzso zzso Bethesda, zzso National Institutes of Health, zzso zzso zzso Research zzso zzso zzso Testing for Drugs of zzso zzso zzso zzso Bethesda, zzso National Institutes of Health, zzso zzso zzso Research zzso zzso The zzso of zzso Drug zzso zzso the zzso of zzso zzso zzso zzso zzso zzso zzso Bethesda, zzso National Institutes of Health, zzso 

